US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

UpStream Bio Inc.

25.01

-3.9700-13.70%

Post-market: 25.510.5000+2.00%17:45 EST

Volume:839.14K

Turnover:21.79M

Market Cap:1.35B

PE:-9.53

High:29.89

Open:29.61

Low:24.61

Close:28.98

52wk High:33.00

52wk Low:5.14

Shares:54.04M

Float Shares:31.42M

Volume Ratio:1.39

T/O Rate:2.67%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.6241

EPS(LYR):-5.5835

ROE:-40.80%

ROA:-28.15%

PB:3.57

PE(LYR):-4.48

Loading ...

Overview Company News Filings

Upstream Bio Inc. to Participate in Stifel 2025 Virtual Immunology and Inflammation Forum

Upstream Bio Shares Rise on Positive Data for Sinus-Disease Treatment

Upstream Bio Inc - Verekitug Meets Primary and Secondary Endpoints in Phase 2 Trial

THOMSON REUTERS

Upstream Bio Reports Positive Top-Line Results From the Phase 2 Vibrant Trial of Verekitug for the Treatment of Chronic Rhinosinusitis With Nasal Polyps (Crswnp)

THOMSON REUTERS

Upstream Bio Inc: No Serious Adverse Events (Saes) Observed; Generally Well Tolerated Safety Profile Consistent With Previous Studies

THOMSON REUTERS

Upstream Bio Inc. Announces Upcoming Release of Phase 2 VIBRANT Trial Results for Verekitug in Treating Chronic Rhinosinusitis with Nasal Polyps

Earnings Flash (UPB) Upstream Bio Posts Q2 Net Loss $0.74 a Share, vs. FactSet Est of $0.61 Loss

MT Newswires Live

Upstream Bio Q2 EPS $(0.74) Misses $(0.61) Estimate,

Upstream Bio Q2 Sales $937.00K Beat $317.50K Estimate

Upstream Bio Inc. Reports Widened Net Loss to $40M in Q2 2025, Driven by Increased R&D and Administrative Expenses

Press Release: Fannie Mae Announces Winners of its Latest Non-Performing Loan Sale

Arbor Realty Trust Reports Second Quarter 2025 Results and Declares Dividend of $0.30 per Share

BRIEF-Upstream Bio Announces First Patient Dosed In Phase 2 Clinical Trial Of Verekitug

Upstream Bio Inc. Conducted Annual Stockholders Meeting

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/UPB/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"UPB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"UPB\",,,,,undefined,":{"symbol":"UPB","market":"US","secType":"STK","nameCN":"UpStream Bio Inc.","latestPrice":25.01,"timestamp":1764709200000,"preClose":28.98,"halted":0,"volume":839143,"hourTrading":{"tag":"盘后","latestPrice":25.51,"preClose":25.01,"latestTime":"17:45 EST","volume":1155,"amount":28896.54999,"timestamp":1764715536977},"delay":0,"floatShares":31417476,"shares":54038591,"eps":-2.624147,"marketStatus":"Post-Mkt","change":-3.97,"latestTime":"12-02 18:11:51 EST","open":29.61,"high":29.89,"low":24.61,"amount":21793826.759647,"amplitude":0.182195,"askPrice":37.44,"askSize":100,"bidPrice":20.58,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-2.624147,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1764723600000},"marketStatusCode":4,"adr":0,"listingDate":1728619200000,"exchange":"NASDAQ","adjPreClose":28.98,"preHourTrading":{"tag":"盘前","latestPrice":29.95,"preClose":28.98,"latestTime":"08:42 EST","volume":2942,"amount":86414.342184,"timestamp":1764682968901},"postHourTrading":{"tag":"盘后","latestPrice":25.51,"preClose":25.01,"latestTime":"17:45 EST","volume":1155,"amount":28896.54999,"timestamp":1764715536977},"volumeRatio":1.392588,"impliedVol":0.9574,"impliedVolPercentile":0.7315},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"UPB\",,,,,undefined,":{"symbol":"UPB","floatShares":31417476,"roa":"-28.15%","roe":"-40.80%","lyrEps":-5.58348,"volumeRatio":1.392588,"shares":54038591,"dividePrice":0,"high":29.89,"amplitude":0.182195,"preClose":28.98,"low":24.61,"week52Low":5.14,"pbRate":"3.57","psRate":"482.85","week52High":33,"institutionHeld":0,"latestPrice":25.01,"eps":-2.624147,"divideRate":0,"volume":839143,"delay":0,"ttmEps":-2.624147,"open":29.61,"prevYearClose":16.44,"prevWeekClose":28.6,"prevMonthClose":28.6,"prevQuarterClose":18.81,"fiveDayClose":26.05,"twentyDayClose":25.02,"sixtyDayClose":18.73},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/UPB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-06","symbol":"UPB","fiscalQuarterEnding":"2025/03","expectedEps":-0.49,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746504000000,"reportTimeType":"pre","actualEps":-0.51},{"market":"US","date":"2025-03-12","symbol":"UPB","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1741752000000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"UPB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"UPB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2,"buy":0.8,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8,"analysts":5,"updateTime":1760590800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/UPB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"UPB","date":"2025-12-01","current":-11.043589,"percent":0.242958,"low":-36.237602,"twenty":-16.389035,"median":-9.06956,"eighty":-7.396957,"high":-5.184222,"avg":-12.024248,"sd":7.244108,"marketCap":1545503702},"quantilePoints":[{"date":"2024-10-11","current":-21.547111,"twenty":-21.096119,"median":-20.419631,"eighty":-19.743142,"marketCap":872808815},{"date":"2024-10-18","current":-29.91246,"twenty":-29.856691,"median":-29.151973,"eighty":-22.814588,"marketCap":1211664002},{"date":"2024-10-25","current":-33.154958,"twenty":-33.128498,"median":-29.931472,"eighty":-28.137991,"marketCap":1343007876},{"date":"2024-10-31","current":-32.943274,"twenty":-33.154958,"median":-32.429578,"eighty":-29.151973,"marketCap":1334433205},{"date":"2024-11-08","current":-35.748083,"twenty":-33.28726,"median":-32.943274,"eighty":-29.633615,"marketCap":1448047598},{"date":"2024-11-15","current":-26.036965,"twenty":-33.27403,"median":-32.40745,"eighty":-26.47861,"marketCap":1390295829},{"date":"2024-11-22","current":-17.866537,"twenty":-33.154958,"median":-29.91246,"eighty":-25.555171,"marketCap":954019497},{"date":"2024-11-29","current":-21.951751,"twenty":-33.154958,"median":-29.151973,"eighty":-21.870823,"marketCap":1172157663},{"date":"2024-12-06","current":-22.082237,"twenty":-33.144374,"median":-26.689395,"eighty":-21.903572,"marketCap":1179125222},{"date":"2024-12-13","current":-20.486294,"twenty":-33.088806,"median":-26.036965,"eighty":-21.589777,"marketCap":1093906626},{"date":"2024-12-20","current":-16.672089,"twenty":-32.969734,"median":-24.742143,"eighty":-20.201232,"marketCap":890239542},{"date":"2024-12-27","current":-19.517686,"twenty":-32.858694,"median":-23.382078,"eighty":-19.472518,"marketCap":1042185906},{"date":"2025-01-03","current":-16.36093,"twenty":-32.784605,"median":-22.553994,"eighty":-19.153329,"marketCap":873624596},{"date":"2025-01-10","current":-16.250519,"twenty":-32.617811,"median":-22.077219,"eighty":-18.486847,"marketCap":867728970},{"date":"2025-01-17","current":-10.92067,"twenty":-31.635576,"median":-21.951751,"eighty":-17.320504,"marketCap":583131018},{"date":"2025-01-24","current":-10.810259,"twenty":-29.950484,"median":-21.600443,"eighty":-16.501454,"marketCap":577235392},{"date":"2025-01-31","current":-11.041119,"twenty":-29.91246,"median":-20.852659,"eighty":-16.230444,"marketCap":589562611},{"date":"2025-02-07","current":-8.561886,"twenty":-29.633615,"median":-19.703378,"eighty":-11.472726,"marketCap":457179006},{"date":"2025-02-14","current":-7.3574,"twenty":-29.151973,"median":-19.472518,"eighty":-10.92067,"marketCap":392863085},{"date":"2025-02-21","current":-8.260764,"twenty":-28.137991,"median":-19.276941,"eighty":-10.810259,"marketCap":441100026},{"date":"2025-02-28","current":-7.839194,"twenty":-27.097043,"median":-19.030874,"eighty":-9.965112,"marketCap":418589453},{"date":"2025-03-07","current":-8.451474,"twenty":-26.562924,"median":-18.338294,"eighty":-8.834903,"marketCap":451283380},{"date":"2025-03-14","current":-7.737899,"twenty":-26.318012,"median":-17.866537,"eighty":-8.491624,"marketCap":485986508},{"date":"2025-03-21","current":-6.875286,"twenty":-26.085144,"median":-16.857781,"eighty":-8.411325,"marketCap":431809204},{"date":"2025-03-28","current":-5.816236,"twenty":-26.012875,"median":-16.36093,"eighty":-8.168077,"marketCap":365294494},{"date":"2025-04-04","current":-5.380659,"twenty":-25.645507,"median":-16.240482,"eighty":-7.936302,"marketCap":337937638},{"date":"2025-04-11","current":-5.466066,"twenty":-24.254326,"median":-13.751211,"eighty":-7.734483,"marketCap":343301728},{"date":"2025-04-17","current":-7.191293,"twenty":-23.886958,"median":-11.472726,"eighty":-7.5722,"marketCap":451656335},{"date":"2025-04-25","current":-7.652492,"twenty":-23.286723,"median":-11.041119,"eighty":-7.514132,"marketCap":480622419},{"date":"2025-05-02","current":-7.693506,"twenty":-22.857123,"median":-10.850408,"eighty":-7.502769,"marketCap":483198327},{"date":"2025-05-09","current":-6.005612,"twenty":-22.499792,"median":-10.810259,"eighty":-7.378434,"marketCap":475536334},{"date":"2025-05-16","current":-5.964849,"twenty":-22.162536,"median":-10.288315,"eighty":-7.189481,"marketCap":472308712},{"date":"2025-05-23","current":-6.324914,"twenty":-22.076215,"median":-9.921951,"eighty":-6.77963,"marketCap":500819374},{"date":"2025-05-30","current":-6.352089,"twenty":-22.02402,"median":-9.013568,"eighty":-6.524152,"marketCap":502971123},{"date":"2025-06-06","current":-7.357554,"twenty":-21.951751,"median":-8.668839,"eighty":-6.524152,"marketCap":582585803},{"date":"2025-06-13","current":-7.853492,"twenty":-21.855392,"median":-8.531773,"eighty":-6.551855,"marketCap":621855206},{"date":"2025-06-20","current":-7.228474,"twenty":-21.688772,"median":-8.441437,"eighty":-6.588317,"marketCap":572364999},{"date":"2025-06-27","current":-7.432284,"twenty":-21.589777,"median":-8.421362,"eighty":-6.683973,"marketCap":588503110},{"date":"2025-07-03","current":-7.60892,"twenty":-21.547111,"median":-8.293047,"eighty":-6.875286,"marketCap":602489473},{"date":"2025-07-11","current":-8.043715,"twenty":-21.219023,"median":-8.229183,"eighty":-7.004282,"marketCap":636917443},{"date":"2025-07-18","current":-7.500221,"twenty":-20.486294,"median":-8.00983,"eighty":-7.116503,"marketCap":593882481},{"date":"2025-07-25","current":-9.06956,"twenty":-20.325696,"median":-7.964314,"eighty":-7.165671,"marketCap":718145935},{"date":"2025-08-01","current":-10.401121,"twenty":-19.703378,"median":-8.043715,"eighty":-7.186764,"marketCap":823581592},{"date":"2025-08-08","current":-8.173881,"twenty":-19.517686,"median":-8.19076,"eighty":-7.191293,"marketCap":853925323},{"date":"2025-08-15","current":-9.608438,"twenty":-19.472518,"median":-8.256445,"eighty":-7.228474,"marketCap":1003793530},{"date":"2025-08-22","current":-9.154334,"twenty":-19.472518,"median":-8.332111,"eighty":-7.228474,"marketCap":956353234},{"date":"2025-08-29","current":-8.648626,"twenty":-19.29215,"median":-8.429698,"eighty":-7.242061,"marketCap":903521996},{"date":"2025-09-05","current":-10.155428,"twenty":-19.267816,"median":-8.442215,"eighty":-7.274671,"marketCap":1060937523},{"date":"2025-09-12","current":-9.247219,"twenty":-19.117195,"median":-8.531282,"eighty":-7.282823,"marketCap":966056931},{"date":"2025-09-19","current":-8.911801,"twenty":-19.040911,"median":-8.561886,"eighty":-7.298422,"marketCap":931015804},{"date":"2025-09-26","current":-8.416414,"twenty":-18.814066,"median":-8.561394,"eighty":-7.303028,"marketCap":879262754},{"date":"2025-10-03","current":-9.592957,"twenty":-18.486847,"median":-8.591998,"eighty":-7.324944,"marketCap":1002176247},{"date":"2025-10-10","current":-10.212191,"twenty":-18.290115,"median":-8.630565,"eighty":-7.351996,"marketCap":1066867560},{"date":"2025-10-17","current":-11.4971,"twenty":-18.113457,"median":-8.648626,"eighty":-7.357523,"marketCap":1201102033},{"date":"2025-10-24","current":-10.903668,"twenty":-17.908694,"median":-8.694854,"eighty":-7.362988,"marketCap":1139106192},{"date":"2025-10-31","current":-13.298037,"twenty":-17.320504,"median":-8.903157,"eighty":-7.366819,"marketCap":1389245933},{"date":"2025-11-07","current":-10.460565,"twenty":-17.071577,"median":-8.919541,"eighty":-7.375835,"marketCap":1278553063},{"date":"2025-11-14","current":-10.319087,"twenty":-16.746366,"median":-8.953083,"eighty":-7.3842,"marketCap":1261260713},{"date":"2025-11-21","current":-11.035322,"twenty":-16.535581,"median":-9.042102,"eighty":-7.390371,"marketCap":1348803231},{"date":"2025-11-28","current":-12.644639,"twenty":-16.41714,"median":-9.068084,"eighty":-7.395598,"marketCap":1545503702},{"date":"2025-12-01","current":-12.644639,"twenty":-16.389035,"median":-9.06956,"eighty":-7.396957,"marketCap":1545503702}],"updateTime":1764679843430},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"UPB\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2566699160","title":"Upstream Bio Inc. to Participate in Stifel 2025 Virtual Immunology and Inflammation Forum","url":"https://stock-news.laohu8.com/highlight/detail?id=2566699160","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566699160?lang=en_us&edition=fundamental","pubTime":"2025-09-09 19:00","pubTimestamp":1757415619,"startTime":"0","endTime":"0","summary":"Upstream Bio Inc. , a company focused on developing treatments for inflammatory diseases, will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on September 15, 2025. The event will feature Rand Sutherland, MD, Chief Executive Officer of Upstream Bio. A live webcast of the chat will be accessible on the company's website, with a replay available after the presentation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief via GlobeNewswire  on September 09, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nNDL7JPWF0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4588","IE00BGHQF748.EUR","BK4127","SF","BK4139","BK4112","LU0314104364.USD","LU2095319765.USD","IE00BKPKM429.USD","NDAQ","BK4585","LU2210150020.SGD","UPB","IE00B64PRP62.GBP","LU2210149790.SGD"],"gpt_icon":0},{"id":"2564382331","title":"Upstream Bio Shares Rise on Positive Data for Sinus-Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2564382331","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564382331?lang=en_us&edition=fundamental","pubTime":"2025-09-03 01:56","pubTimestamp":1756835760,"startTime":"0","endTime":"0","summary":"Upstream Bio shares rose after the biotechnology company reported positive results for a trial of a sinus-disease treatment.The stock advanced 7.1% to $18.34 on Tuesday. Shares have gained 12% this year.Results from a Phase 2 trial showed verekitug met the primary endpoint and key secondary endpoints in treating rhinosinusitis with nasal polyps, the Waltham, Mass., clinical-stage company said Tuesday.The trial data showed statistically significant reductions in endoscopic nasal polyp score and nasal congestion score. Treatment with verekitug also resulted in significant reduction in the need for surgery or systemic corticosteroids, Upstream said.The trial was designed to produce data that would support submissions for product approval, Upstream said. The company plans to engage with global regulatory authorities to continue verekitug's development.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Upstream Bio Shares Rise on Positive Data for Sinus-Disease Treatment","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UPB","BK4139"],"gpt_icon":1},{"id":"2564880362","title":"Upstream Bio Inc - Verekitug Meets Primary and Secondary Endpoints in Phase 2 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2564880362","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564880362?lang=en_us&edition=fundamental","pubTime":"2025-09-02 18:00","pubTimestamp":1756807201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nTUA3XT8ZV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["UPB","BK4139"],"gpt_icon":0},{"id":"2564803645","title":"Upstream Bio Reports Positive Top-Line Results From the Phase 2 Vibrant Trial of Verekitug for the Treatment of Chronic Rhinosinusitis With Nasal Polyps (Crswnp)","url":"https://stock-news.laohu8.com/highlight/detail?id=2564803645","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564803645?lang=en_us&edition=fundamental","pubTime":"2025-09-02 18:00","pubTimestamp":1756807201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nTUA3XT8ZV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["UPB","BK4139"],"gpt_icon":0},{"id":"2564803180","title":"Upstream Bio Inc: No Serious Adverse Events (Saes) Observed; Generally Well Tolerated Safety Profile Consistent With Previous Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2564803180","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564803180?lang=en_us&edition=fundamental","pubTime":"2025-09-02 18:00","pubTimestamp":1756807201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nTUA3XT8ZV:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["UPB","BK4139"],"gpt_icon":0},{"id":"2564847514","title":"Upstream Bio Inc. Announces Upcoming Release of Phase 2 VIBRANT Trial Results for Verekitug in Treating Chronic Rhinosinusitis with Nasal Polyps","url":"https://stock-news.laohu8.com/highlight/detail?id=2564847514","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564847514?lang=en_us&edition=fundamental","pubTime":"2025-09-02 05:00","pubTimestamp":1756760413,"startTime":"0","endTime":"0","summary":"Upstream Bio Inc. Announces Upcoming Release of Phase 2 VIBRANT Trial Results for Verekitug in Treating Chronic Rhinosinusitis with Nasal Polyps. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief via GlobeNewswire  on September 01, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250901:nNDLyXZgH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","LU0314104364.USD","UPB","IE00BGHQF748.EUR","BK4585","BK4588","LU2210149790.SGD","NDAQ","BK4112","LU2095319765.USD","BK4139","IE00BKPKM429.USD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD"],"gpt_icon":1},{"id":"2557379278","title":"Earnings Flash (UPB) Upstream Bio Posts Q2 Net Loss $0.74 a Share, vs. FactSet Est of $0.61 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2557379278","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557379278?lang=en_us&edition=fundamental","pubTime":"2025-08-06 19:40","pubTimestamp":1754480412,"startTime":"0","endTime":"0","summary":"Earnings Flash (UPB) Upstream Bio Posts Q2 Net Loss $0.74 a Share, vs. FactSet Est of $0.61 Loss","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["UPB"],"gpt_icon":0},{"id":"2557376258","title":"Upstream Bio Q2 EPS $(0.74) Misses $(0.61) Estimate,","url":"https://stock-news.laohu8.com/highlight/detail?id=2557376258","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557376258?lang=en_us&edition=fundamental","pubTime":"2025-08-06 19:22","pubTimestamp":1754479329,"startTime":"0","endTime":"0","summary":"Upstream Bio Q2 EPS $(0.74) Misses $(0.61) Estimate,","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/46892729/upstream-bio-q2-eps-0-74-misses-0-61-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UPB"],"gpt_icon":0},{"id":"2557376933","title":"Upstream Bio Q2 Sales $937.00K Beat $317.50K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2557376933","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557376933?lang=en_us&edition=fundamental","pubTime":"2025-08-06 19:20","pubTimestamp":1754479203,"startTime":"0","endTime":"0","summary":"Upstream Bio Q2 Sales $937.00K Beat $317.50K Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/46892616/upstream-bio-q2-sales-937-00k-beat-317-50k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UPB"],"gpt_icon":0},{"id":"2557376862","title":"Upstream Bio Inc. Reports Widened Net Loss to $40M in Q2 2025, Driven by Increased R&D and Administrative Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2557376862","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557376862?lang=en_us&edition=fundamental","pubTime":"2025-08-06 19:01","pubTimestamp":1754478090,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief via GlobeNewswire  on August 06, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nNDL10Rs99:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU2095319765.USD","IE00B64PRP62.GBP","UPB","LU2210150020.SGD","BK4112","IE00BGHQF748.EUR","BK4585","BK4139","LU2210149790.SGD","BK4588","IE00BKPKM429.USD","NDAQ","LU0314104364.USD"],"gpt_icon":0},{"id":"2557318987","title":"Press Release: Fannie Mae Announces Winners of its Latest Non-Performing Loan Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2557318987","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557318987?lang=en_us&edition=fundamental","pubTime":"2025-08-05 23:00","pubTimestamp":1754406000,"startTime":"0","endTime":"0","summary":"WASHINGTON, Aug. 5, 2025 /PRNewswire/ -- Fannie Mae  today announced the results of its twenty-seventh non-performing loan sale transaction. The deal, announced on July 8, 2025, included the sale of 1,304 deeply delinquent loans totaling $285 million in unpaid principal balance , offered in two pools. The winning bidder for Pool 1 was Residential Credit Opportunities Trust X-C, and for Pool 2 was RCF II Loan Acquisition, LP. The transaction is expected to close on September 19, 2025. The deal was marketed with BofA Securities, Inc. as advisor.The loan pools awarded in this most recent transaction include:. -- Pool 1: 332 loans with an aggregate UPB of $73,092,445; average loan size. of $220,158; weighted average note rate of 4.45%; and weighted average. -- Pool 2: 972 loans with an aggregate UPB of $211,965,249; average loan. size of $218,071; weighted average note rate of 4.39%; and weighted. Interested bidders can register for ongoing announcements, training, and other information he","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4195","FNMA","BK4229","BK4139","UPB","BK4232","R"],"gpt_icon":0},{"id":"2556816824","title":"Arbor Realty Trust Reports Second Quarter 2025 Results and Declares Dividend of $0.30 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2556816824","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556816824?lang=en_us&edition=fundamental","pubTime":"2025-08-01 20:30","pubTimestamp":1754051400,"startTime":"0","endTime":"0","summary":"Company Highlights: GAAP net income of $0.12 per diluted common shareDistributable earnings1 of $0.25, or $0.30 per diluted common share, excluding $10.5 million of realized losses from the sale of tw","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/01/3125776/0/en/Arbor-Realty-Trust-Reports-Second-Quarter-2025-Results-and-Declares-Dividend-of-0-30-per-Share.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4110","BK4139","ABR","UPB"],"gpt_icon":0},{"id":"2549418305","title":"BRIEF-Upstream Bio Announces First Patient Dosed In Phase 2 Clinical Trial Of Verekitug","url":"https://stock-news.laohu8.com/highlight/detail?id=2549418305","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549418305?lang=en_us&edition=fundamental","pubTime":"2025-07-08 19:26","pubTimestamp":1751974001,"startTime":"0","endTime":"0","summary":"BRIEF-Upstream Bio Announces First Patient Dosed In Phase 2 Clinical Trial Of Verekitug July 8 (Reuters) - Upstream Bio Inc UPB.O:UPSTREAM BIO ANNOUNCES FIRST PATIENT DOSED IN PHASE 2 CLINICAL TRIAL O","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nTUA6YFB9X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","UPB"],"gpt_icon":0},{"id":"2543654223","title":"Upstream Bio Inc. Conducted Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2543654223","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543654223?lang=en_us&edition=fundamental","pubTime":"2025-06-13 04:19","pubTimestamp":1749759572,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 12, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250612:nNDL3cPyVQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UPB","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":34,"code":"91000000","status":"200"}]}}